Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Rhea-AI Summary

Aspire Biopharma (NASDAQ:ASBP) announced that Interim CEO Kraig Higginson will present and hold 1x1 investor meetings at the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference on October 8-9, 2025.

The virtual presentation is scheduled for Wednesday, October 8 at 1:00 PM ET, with 1x1 meetings on October 8-9. Management will discuss pipeline progress and upcoming milestones, including a planned H2 2025 FDA meeting request and targeted NDA submission in H2 2025 for the lead sublingual high-dose aspirin program, and formulation completion and Phase 1 PK cross-over studies for sublingual semaglutide and a needle-free ED medication in H1–mid‑2026. For registration, investors are directed to the Noble conference site.

• Showcasing Disruptive Sublingual Drug Delivery Technology with Lead Program Targeting H2 2025 FDA Submission for Sublingual Aspirin

• Highlighting Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and a More-Rapid ED Medication

• Presentation and 1x1 Investor Meetings Scheduled Across the Two-Day Virtual Conference

ESTERO, FLORIDA / ACCESS Newswire / October 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending sublingual drug delivery technology, today announced that Kraig Higginson, Interim CEO of Aspire Biopharma will be presenting and participating in 1x1 meetings at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference.

The presentation will feature updates on the company's pipeline progress and key milestones expected throughout the remainder of 2025 and early 2026. Aspire is focusing its pipeline on reformulating approved drugs for multi-billion-dollar markets by utilizing its disruptive, patent-pending sublingual delivery technology.

Virtual Presentation - Wednesday, October 8^th at 1:00 p.m. Eastern

Virtual 1x1 Meetings - Wednesday, October 8^th and Thursday, October 9th

Format - Corporate presentations with fireside-style Q&A sessions proctored by Noble's analysts and bankers, along with scheduled 1×1 meetings with qualified investors

Anticipated Milestones to be Discussed

• Sublingual High-dose Aspirin (Lead Program)

  • H2 2025: Request meeting with FDA to discuss 505(b)(2) pathway.

  • H2 2025: Target submission of New Drug Application (NDA).

• Sublingual ED medication

  • H1 2026: Finalize formulation and manufacture test product.

  • Mid-2026: Initiate Phase 1 pharmacokinetic (PK) clinical cross-over study.

• Sublingual Semaglutide

  • H1 2026: Finalize formulation and manufacture test product.

  • H1 2026 Initial Phase 1 pharmacokinetic clinical cross-over study.

For more information or to register for the conference to please visit https://nobleconference.com/virtual-october/

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements. "We don't make the drugs…We make them work better for your body".

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact

Brett Maas
Hayden IR: (646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR: (646)-755-7412
james@haydenir.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

When will Aspire Biopharma (ASBP) present at the Noble Capital Markets 2025 virtual conference?

Aspire will present on Wednesday, October 8, 2025 at 1:00 PM ET.

What pipeline milestones will ASBP discuss at the October 8–9, 2025 conference?

Management will discuss a planned H2 2025 FDA meeting request, targeted NDA submission H2 2025 for sublingual high‑dose aspirin, and H1–mid‑2026 milestones for semaglutide and ED programs.

How can investors attend Aspire Biopharma's (ASBP) virtual presentation on October 8, 2025?

Register via the Noble conference website at https://nobleconference.com/virtual-october.

Will Aspire (ASBP) conduct investor 1x1 meetings at the Noble conference?

Yes. Aspire's management will hold scheduled virtual 1x1 meetings on October 8 and 9, 2025 with qualified investors.

What is the timing for ASBP's sublingual semaglutide and ED medication studies announced for the conference?

Aspire targets H1 2026 completion of formulation and initial Phase 1 PK cross‑over studies for semaglutide; ED program formulation in H1 2026 and Phase 1 PK initiation in mid‑2026.